Binkley N C, Krueger D C, Engelke J A, Foley A L, Suttie J W
Institute on Aging, Department of Medicine, University of Wisconsin, Madison, WI, USA.
Am J Clin Nutr. 2000 Dec;72(6):1523-8. doi: 10.1093/ajcn/72.6.1523.
Subclinical vitamin K insufficiency, manifested by under-gamma-carboxylation of the bone matrix protein osteocalcin, may be common.
Our objective was to delineate the prevalence of submaximal gamma-carboxylation as assessed by response to phylloquinone supplementation and to evaluate the effect of this intervention on skeletal turnover in healthy North American adults.
Healthy subjects (n = 219), approximately equally distributed by sex and age (18-30 y and >/=65 y), received daily phylloquinone (1000 microg) or placebo for 2 wk. Serum undercarboxylated osteocalcin (ucOC) and total osteocalcin, N:-telopeptides of type I collagen (NTx), bone-specific alkaline phosphatase (BSAP), and phylloquinone concentrations were measured at baseline and after weeks 1 and 2.
At baseline, the mean serum phylloquinone concentration was lower in the young than in the old group; there was no effect of sex. Concomitantly, baseline %ucOC was highest in the young and lowest in the old men (P: < 0.0001) but did not differ significantly by age in women. After supplementation, serum phylloquinone concentration increased approximately 10-fold (P: < 0.0001) at week 1 (from 0.93 +/- 0.08 to 8.86 +/- 0.70 nmol/L, x+/- SEM); this was sustained through week 2. Among all supplemented groups, mean %ucOC decreased from 7.6% to 3. 4% without significant differences by age or sex; 102 of 112 subjects had a >1% decrease. Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration.
Usual dietary practices in this population did not provide adequate vitamin K for maximal osteocalcin carboxylation. Phylloquinone supplementation reduced serum osteocalcin concentration but did not alter other markers of serum bone turnover.
亚临床维生素K缺乏症,表现为骨基质蛋白骨钙素的γ羧化不足,可能很常见。
我们的目的是通过对叶绿醌补充剂的反应来描述亚最大γ羧化的患病率,并评估这种干预对健康北美成年人骨骼转换的影响。
健康受试者(n = 219),按性别和年龄(18 - 30岁和≥65岁)大致均匀分布,接受每日叶绿醌(1000微克)或安慰剂治疗2周。在基线以及第1周和第2周后测量血清未羧化骨钙素(ucOC)、总骨钙素、I型胶原N端肽(NTx)、骨特异性碱性磷酸酶(BSAP)和叶绿醌浓度。
在基线时, 年轻组的平均血清叶绿醌浓度低于老年组;性别对此无影响。同时,基线时%ucOC在年轻人中最高,在老年男性中最低(P < 0.0001),但在女性中按年龄无显著差异。补充后,血清叶绿醌浓度在第1周增加了约10倍(P < 0.0001)(从0.93±0.08至8.86±0.70纳摩尔/升,x±SEM);这种情况持续到第2周。在所有补充组中,平均%ucOC从7.6%降至3.4%,年龄或性别之间无显著差异;112名受试者中有102名下降超过1%。叶绿醌补充剂降低了血清骨钙素,但未改变NTx或BSAP浓度。
该人群的日常饮食习惯未提供足够的维生素K以实现最大程度的骨钙素羧化。叶绿醌补充剂降低了血清骨钙素浓度,但未改变血清骨转换的其他标志物。